Pfizer's acquisition of Metsera could significantly influence the dynamics of mergers and acquisitions within the biotech sector.
UnitedHealthcare has announced it will cease reimbursing physicians for remotely monitoring patient data collected at home, a move that conflicts with existing Medicare policies.
Is the turmoil within the FDA truly responsible for drugmakers' recent setbacks? The situation is complex and cannot be solely attributed to the agency's internal issues.
In the latest edition of STAT's Health Tech newsletter, the FDA's digital health advisory committee is set to discuss potential regulations for therapy chatbots, highlighting the agency's focus on digital health innovation and patient safety.
Mark Cuban Cost Plus Drug Company aims to disrupt pharmaceutical pricing by offering a biosimilar version of Stelara, a popular drug by Johnson & Johnson, potentially making the treatment more affordable for patients.
For individuals struggling to maintain relationships despite long-term treatment, AI chatbots can provide meaningful and therapeutic assistance.
AI-powered autonomous coding is becoming a key area of contention between healthcare providers and insurance companies, as it transforms medical billing and administrative processes.
Pfizer has launched a second lawsuit targeting Novo Nordisk and the obesity biotech startup Metsera, claiming that Novo Nordisk's efforts to acquire Metsera are anticompetitive practices.
Exclusive: A detailed look into why Moderna, once a company hailed for its life-saving innovation, is currently undergoing its most severe crisis in 15 years.
The Trump administration has significantly cut the workforce of the federal agency responsible for mental health and addiction treatment, reducing its staff by over 50%.